Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

INTRODUCTION

G. M. Verleden, M. Decramer, R. Gosselink, M. Demedts
European Respiratory Review 2005 14: 1; DOI: 10.1183/09058180.05.00009400
G. M. Verleden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Decramer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Gosselink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Demedts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

During the last 10 yrs tremendous efforts have been made to elucidate the pathophysiological mechanisms of chronic obstructive pulmonary disease (COPD) and to improve the treatment of this debilitating disease. This has resulted in several international guidelines 1–3 and revised guidelines 4, 5 regarding the diagnosis, staging and treatment of this disease. However, despite intensive research, treatment of COPD remains symptomatic, and up until now, no single drug is able to alter the natural evolution of the disease. Indeed, only smoking cessation is known to improve the progression of the disease, and neither anti-inflammatory drugs, nor long-acting anticholinergics/β2-agonists seem to influence the natural decline in FEV1, although they may impact on quality of life and exacerbations frequencies 6.

The purpose of this international symposium “COPD: a clinical update”, organised by the Dept of Respiratory Diseases of the University Hospital Gasthuisberg, Katholieke Universiteit, Leuven, Belgium, March 11–13, 2004, was to provide a clinical update of several issues regarding COPD. Some 40 clinical and basic researchers, and internationally well-known experts in the field from all over Europe were brought together to discuss issues on exacerbations and progression of COPD and current and new treatment options. This issue of the European Respiratory Review contains the articles on current and new treatment options presented on the postgraduate symposium on March 13.

This symposium was accredited as a “European School of Respiratory Medicine” seminar, and was sponsored by GlaxoSmithKline (GSK), Belgium. This occurred in the framework of the “GSK Chair in Respiratory Pharmacology at the Katholieke Universiteit, Leuven”, attributed to G.M. Verleden. The sponsor is not responsible for the content of this Review.

It is very much hoped that this European Respiratory Review will provide an interesting synthesis and update of current and upcoming new drug treatments for chronic obstructive pulmonary disease. We are very grateful to P.S. Burge, Editor-in-Chief of the European Respiratory Review for granting us the privilege of publishing this symposium.

    • © ERSJ Ltd

    References

    1. ↵
      Siafakis NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398–1420.
    2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77–S121.
    3. ↵
      The COPD guidelines group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52: Suppl. 5 S1–S28.
      OpenUrlPubMed
    4. ↵
      Bateman ED, Feldman C, O'Brien J, et al. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision. S Afr Med J 2004; 94: 559–575.
      OpenUrlPubMed
    5. ↵
      National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in primary and secondary care. Thorax 2004; 59: Suppl. 1 1–232.
      OpenUrlFREE Full Text
    6. ↵
      National Institutes of Health, National Heart and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. NIH Publication No. 2701A. March 2001
    Next
    Back to top
    View this article with LENS
    Vol 14 Issue 94 Table of Contents
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    INTRODUCTION
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    INTRODUCTION
    G. M. Verleden, M. Decramer, R. Gosselink, M. Demedts
    European Respiratory Review Sep 2005, 14 (94) 1; DOI: 10.1183/09058180.05.00009400

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    INTRODUCTION
    G. M. Verleden, M. Decramer, R. Gosselink, M. Demedts
    European Respiratory Review Sep 2005, 14 (94) 1; DOI: 10.1183/09058180.05.00009400
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Smoking cessation: a clinical update
    • Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis
    • Winners of the ERS Annual Awards 2007
    Show more Introduction

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERR

    • Journal information
    • Editorial board
    • Press
    • Permissions and reprints
    • Advertising
    • Sponsorship

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN: 0905-9180
    Online ISSN: 1600-0617

    Copyright © 2023 by the European Respiratory Society